Published 3 issues per year
ISSN Print: 0892-0915
ISSN Online: 2375-0014
Felbamate: Clinical and Molecular Aspects of a Unique Antiepileptic Drug
Get access
ABSTRACT
Felbamate was launched in 1993 in the U.S. as a "new generation" antiepileptic drug (AED) with a unique mechanism of action. It proved efficacious in patients refractory to other AEDs and was particularly beneficial in children suffering from Lennox-Gastaut syndrome, being the first drug shown to be effective at treating this condition in controlled trials. Following the occurrence of rare cases of aplastic anemia and of hepatic failure associated with the use of felbamate during early 1994, a "black-box" warning was added to the drug's package insert. Despite this, felbamate continues to be used in many patients, although not as a first-line treatment. Felbamate's dual mechanism of action−enhancing the GABA system while inhibiting excitatory amino acid responses−may explain its efficacy in a broad range of epileptic patients. A better understanding of this mechanism may lead to the development of felbamate-like drugs with a better side effect profile.
-
Fridhandler Jonathan D., Coelho Fernando M., Tai Peter, Jette Nathalie, Andrade Danielle M., A comparison of antiepileptic drug therapy in patients with severe intellectual disability and patients with normal intellect, Epilepsy & Behavior, 25, 2, 2012. Crossref
-
Greenwood Robert S., Adverse Effects of Antiepileptic Drugs, Epilepsia, 41, s2, 2000. Crossref
-
Frost Michael, Gates John, Helmers Sandra L., Wheless James W., Levisohn Paul, Tardo Carmelo, Conry Joan A., Vagus Nerve Stimulation in Children with Refractory Seizures Associated with Lennox-Gastaut Syndrome, Epilepsia, 42, 9, 2002. Crossref
-
Kothare Sanjeev V, Kaleyias Joseph, The adverse effects of antiepileptic drugs in children, Expert Opinion on Drug Safety, 6, 3, 2007. Crossref
-
Khaleghi-Rad A., Beyramabadi S. A., Morsali A., Ebrahimi M., Khorzandi-Chenarboo M., Tautomerism of the antiepileptic drug Felbamate: A DFT study, Journal of Structural Chemistry, 58, 2, 2017. Crossref
-
Löscher Wolfgang, Sills Graeme J., White H. Steve, The ups and downs of alkyl‐carbamates in epilepsy therapy: How does cenobamate differ?, Epilepsia, 62, 3, 2021. Crossref
-
Quiroz J A, Singh J, Gould T D, Denicoff K D, Zarate C A, Manji H K, Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology, Molecular Psychiatry, 9, 8, 2004. Crossref
-
Pistovcakova J., Makatsori A., Sulcova A., Jezova D., Felbamate reduces hormone release and locomotor hypoactivity induced by repeated stress of social defeat in mice, European Neuropsychopharmacology, 15, 2, 2005. Crossref